医药材料
Search documents
西安瑞联新材料股份有限公司2025年度业绩快报公告
Xin Lang Cai Jing· 2026-02-13 18:33
Financial Performance - In 2025, the company achieved operating revenue of 1,676.75 million yuan, representing a year-on-year increase of 14.95% [3] - The net profit attributable to the parent company was 310.83 million yuan, up 23.48% year-on-year [3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 305.98 million yuan, reflecting a year-on-year growth of 28.90% [3] Financial Position - As of the end of the reporting period, the company's total assets amounted to 3,646.89 million yuan, an increase of 7.33% from the beginning of the period [4] - The equity attributable to the parent company reached 3,285.55 million yuan, growing by 8.60% compared to the start of the period [4] - The net asset per share attributable to the parent company was 18.93 yuan, which is a 9.32% increase from the beginning of the period [4] Business Performance Factors - The growth in revenue for 2025 was primarily driven by the pharmaceutical and electronic materials sectors, with the pharmaceutical sector benefiting from inventory adjustments by key clients and increased sales of core products [5] - The electronic materials sector saw growth due to successful validation of semiconductor photoresist monomer materials and the introduction of certain packaging materials [5] - The company focused on enhancing operational efficiency and cost reduction, which contributed to improved profitability [5]
瑞联新材2025年度归母净利润3.11亿元,同比增长23.48%
Zhi Tong Cai Jing· 2026-02-13 10:36
Core Viewpoint - 瑞联新材 (688550.SH) reported a revenue of 1.677 billion yuan for the year 2025, representing a year-on-year growth of 14.95%, and a net profit attributable to the parent company of 311 million yuan, reflecting a year-on-year increase of 23.48% [1] Group 1: Financial Performance - The company achieved a revenue of 1.677 billion yuan in 2025, marking a 14.95% increase compared to the previous year [1] - The net profit attributable to the parent company reached 311 million yuan, which is a 23.48% increase year-on-year [1] Group 2: Business Segments - Revenue growth was primarily driven by the pharmaceutical and electronic materials sectors, with the pharmaceutical segment benefiting from customer inventory adjustments and increased sales of core products [1] - The electronic materials segment experienced growth due to successful validation of semiconductor photoresist monomer materials and the introduction of certain packaging materials [1] Group 3: Operational Efficiency - The company focused on enhancing operational management efficiency and cost reduction, implementing measures such as resource optimization and lean processes to improve the management system [1] - Strengthening the coordination between research, production, supply, and sales contributed to reduced production costs and improved profitability [1]
瑞联新材(688550.SH)2025年度归母净利润3.11亿元,同比增长23.48%
智通财经网· 2026-02-13 10:34
Core Viewpoint - 瑞联新材 (688550.SH) reported a revenue of 1.677 billion yuan for the year 2025, reflecting a year-on-year growth of 14.95%, and a net profit attributable to shareholders of 311 million yuan, which is a 23.48% increase year-on-year [1] Group 1: Financial Performance - The company achieved a revenue of 1.677 billion yuan in 2025, marking a 14.95% increase compared to the previous year [1] - The net profit attributable to the parent company's shareholders reached 311 million yuan, representing a year-on-year growth of 23.48% [1] Group 2: Business Segments - Revenue growth was primarily driven by the pharmaceutical and electronic materials sectors, with the pharmaceutical segment benefiting from customer inventory adjustments and increased sales of core products [1] - The electronic materials segment experienced growth due to the successful validation of semiconductor photoresist monomer materials and the introduction of certain packaging materials [1] Group 3: Operational Efficiency - The company focused on enhancing operational management efficiency and cost reduction, implementing measures such as cost-saving initiatives and lean processes to improve the management system [1] - Strengthening the coordination between research, production, supply, and sales helped to lower production costs and enhance profitability [1]